CL2018003418A1 - Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo. - Google Patents

Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.

Info

Publication number
CL2018003418A1
CL2018003418A1 CL2018003418A CL2018003418A CL2018003418A1 CL 2018003418 A1 CL2018003418 A1 CL 2018003418A1 CL 2018003418 A CL2018003418 A CL 2018003418A CL 2018003418 A CL2018003418 A CL 2018003418A CL 2018003418 A1 CL2018003418 A1 CL 2018003418A1
Authority
CL
Chile
Prior art keywords
asparaginase
methods
polyalkylene
preparation
compositions
Prior art date
Application number
CL2018003418A
Other languages
English (en)
Inventor
Gianfranco Fornasini
Nadejda Soukhareva
Christopher Phillips
Original Assignee
Servier Ip Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Ip Uk Ltd filed Critical Servier Ip Uk Ltd
Publication of CL2018003418A1 publication Critical patent/CL2018003418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

ASPECTOS DE LA INVENCIÓN INCLUYEN COMPOSICIONES DE ÓXIDO DE POLIALQUILENO-ASPARAGINASA. EN ALGUNOS CASOS, LA COMPOSICIÓN ES UNA COMPOSICIÓN LIOFILIZADA ESTABLE AL ALMACENAMIENTO. EN ALGUNOS CASOS, LAS COMPOSICIONES LIOFILIZADAS INCLUYEN UNO O MÁS DE UN TAMPÓN, UNA SAL Y UN AZÚCAR. ASPECTOS DE LA INVENCIÓN INCLUYEN ADEMÁS MÉTODOS PARA PREPARAR LAS COMPOSICIONES. LAS COMPOSICIONES ENCUENTRAN USO EN UNA VARIEDAD DE APLICACIONES, POR EJEMPLO, EN EL TRATAMIENTO DE UNA AFECCIÓN NEOPLÁSICA EN UN SUJETO.
CL2018003418A 2016-06-01 2018-11-30 Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo. CL2018003418A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344256P 2016-06-01 2016-06-01
US201662344252P 2016-06-01 2016-06-01
US201662344249P 2016-06-01 2016-06-01

Publications (1)

Publication Number Publication Date
CL2018003418A1 true CL2018003418A1 (es) 2019-05-24

Family

ID=60992770

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003418A CL2018003418A1 (es) 2016-06-01 2018-11-30 Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.

Country Status (30)

Country Link
US (2) US20190240300A1 (es)
EP (2) EP3463308B1 (es)
JP (2) JP7109427B2 (es)
KR (3) KR20230162139A (es)
CN (1) CN109640961B (es)
AU (1) AU2017299374B2 (es)
BR (1) BR112018074823B1 (es)
CA (1) CA3026070A1 (es)
CL (1) CL2018003418A1 (es)
CO (1) CO2018013753A2 (es)
CY (1) CY1124980T1 (es)
DK (1) DK3463308T3 (es)
ES (1) ES2905874T3 (es)
HR (1) HRP20212027T1 (es)
HU (1) HUE057856T2 (es)
IL (2) IL312621A (es)
LT (1) LT3463308T (es)
MX (2) MX2018014916A (es)
MY (1) MY198474A (es)
PH (1) PH12018502540A1 (es)
PL (1) PL3463308T3 (es)
PT (1) PT3463308T (es)
RS (1) RS62979B1 (es)
RU (1) RU2758796C2 (es)
SA (1) SA518400557B1 (es)
SG (1) SG11201810685WA (es)
SI (1) SI3463308T1 (es)
UA (1) UA123020C2 (es)
WO (1) WO2018017190A2 (es)
ZA (2) ZA201807943B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
BR112021011956A2 (pt) * 2018-12-24 2021-09-08 Gennova Biopharmaceuticals Limited Composição liofilizada de pegaspargase
KR20230165799A (ko) * 2021-04-06 2023-12-05 재즈 파마슈티칼즈 아일랜드 리미티드 L-아스파라기나제의 제제
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
DE69033192T3 (de) * 1989-04-19 2004-05-19 Enzon, Inc. Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
TW197439B (es) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
AU704973B2 (en) 1995-04-21 1999-05-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
SI2275119T1 (sl) * 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (fr) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Derives taxol
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
EA002149B1 (ru) * 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
WO1998058927A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
ID28470A (id) 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20050143283A1 (en) 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
KR101177340B1 (ko) 2003-01-06 2012-08-30 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
FI20070455A0 (fi) 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
UA115650C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс арилсульфатази а
RU2441914C1 (ru) 2010-10-06 2012-02-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora
CN102138909B (zh) * 2010-12-30 2013-03-13 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液
CN102657852A (zh) * 2012-05-22 2012-09-12 范铭琦 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用

Also Published As

Publication number Publication date
JP2019521179A (ja) 2019-07-25
BR112018074823A2 (pt) 2019-03-06
HRP20212027T1 (hr) 2022-04-01
JP2022071060A (ja) 2022-05-13
AU2017299374A1 (en) 2018-12-20
IL263349A (en) 2019-01-31
CN109640961A (zh) 2019-04-16
BR112018074823B1 (pt) 2024-02-27
EP3463308A4 (en) 2019-12-18
EP3463308A2 (en) 2019-04-10
US20190240300A1 (en) 2019-08-08
CN109640961B (zh) 2021-11-02
PL3463308T3 (pl) 2022-03-14
RU2018146395A (ru) 2020-07-09
RU2018146395A3 (es) 2020-07-09
SG11201810685WA (en) 2018-12-28
PH12018502540A1 (en) 2019-04-08
AU2017299374B2 (en) 2021-05-27
ES2905874T3 (es) 2022-04-12
IL263349B1 (en) 2024-06-01
CY1124980T1 (el) 2023-01-05
DK3463308T3 (da) 2022-01-31
PT3463308T (pt) 2022-03-11
WO2018017190A2 (en) 2018-01-25
LT3463308T (lt) 2022-02-10
UA123020C2 (uk) 2021-02-03
MY198474A (en) 2023-08-31
EP3463308B1 (en) 2021-12-01
CO2018013753A2 (es) 2019-01-18
CA3026070A1 (en) 2018-01-25
EP4019007A1 (en) 2022-06-29
KR20220165820A (ko) 2022-12-15
JP7109427B2 (ja) 2022-07-29
KR20230162139A (ko) 2023-11-28
SI3463308T1 (sl) 2022-04-29
US20240108701A1 (en) 2024-04-04
RS62979B1 (sr) 2022-03-31
RU2758796C2 (ru) 2021-11-01
IL263349B2 (en) 2024-10-01
KR102473887B1 (ko) 2022-12-06
WO2018017190A3 (en) 2018-03-01
IL312621A (en) 2024-07-01
ZA202202259B (en) 2022-11-30
MX2021015544A (es) 2022-02-23
SA518400557B1 (ar) 2024-02-29
HUE057856T2 (hu) 2022-06-28
KR20190015366A (ko) 2019-02-13
MX2018014916A (es) 2019-07-18
ZA201807943B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
SV2018005778A (es) Derivados aromaticos de sulfonamida
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112016022722B8 (pt) Composto, composição farmacêutica que o comprende e uso do mesmo
UY37261A (es) Formulación combinada de tres compuestos antivirales
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CL2019002928A1 (es) Lipopeptido para inhibir potentemente el vih, derivado, composición farmacéutica y uso del mismo.
EA201892788A1 (ru) Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение
LT2015064A (lt) Karboanhidrazės selektyvūs inhibitoriai